Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent

点击翻译按钮获取中文摘要

Chronic myeloid leukaemia (CML) can usually be treated effectively with long-term tyrosine kinase inhibitor (TKI) therapy. Remarkably, rare patients who achieve excellent responses can stop treatment altogether without relapsing. Detailed studies of these patients in terms of their genetic background, the biology of their leukaemia and their immune response may help us understand how this is possible, leading to new therapeutic approaches to make treatment-free remission more widely achievable.